Physician profile
Celso E Gomez-Sanchez
NPI 1033139555
$2,075.40
in general payments reported to CMS, 2019-2025
16 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $203 · 2021: $274 · 2022: $219 · 2023: $165 · 2024: $352 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.49 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $632.58 | 2019-2025 | Wegovy |
| Corcept Therapeutics | $283.11 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.67 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $160.24 | 2019 | |
| Amgen INC. | $139.02 | 2019-2024 | Tepezza |
| Lilly USA, LLC | $127.72 | 2019-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Shire North American Group INC | $65.45 | 2019 | |
| Abbvie INC. | $63.13 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $52.30 | 2019-2024 | |
| Insulet Corporation | $52.04 | 2019-2024 | Omnipod |
| Ultragenyx Pharmaceutical INC. | $43.40 | 2019-2020 | |
| Pfizer INC. | $29.98 | 2019-2024 | |
| Eisai INC. | $24.44 | 2020 | |
| Tandem Diabetes Care, INC. | $24.32 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $22.00 | 2023 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celso Gomez-Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.